July 8, 2014 | Israeli company Orgenesis, a leader in the fields of cellular therapy and re-generative medicine, signed an agreement with Belgian company MaSTherCell to produce a treatment for diabetes. The Orgenesis subsidiary in Belgium, Orgenesis SPRL, signed an agreement to scale the manufacturing of insulin-producing liver cells to combat diabetes in preparation for Phase I and Phase II clinical trials. Founded by Israelis but now based in the United States, Orgenesis is a development stage company that seeks to cure Type I Diabetes through cellular therapy and regenerative medicine, a process called ‘trans-differentiation.’
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Clean Energy Firm Completes Solar Project In North, South Israel
October 15, 2024
Cannabis Therapy Firm: CBD Jab Reduces Pain In Arthritic Dogs
October 15, 2024
US Government Funding Development Of Israeli Ebola Treatment
October 14, 2024
Security Firm Wins Prison Service Contract For Electronic Monitoring
October 14, 2024
Facebook comments